Abstract
Evidence-based data for the treatment of immune-mediated neuropathies with drugs other than intravenous immunoglobulins (IVIg) are scarce. Standard treatments, such as corticosteroids and plasmapheresis, are not always effective in these diseases. An overview of current clinical practice, existing data and ongoing research into alternatives to immunoglobulin (Ig) therapy for patients with refractory Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) will be explored here.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
